Cite
HARVARD Citation
Mocci, G. et al. (n.d.). P583 Real-life efficacy and safety of Ustekinumab as second- or third-line therapy in Crohn's disease: results from a large Italian cohort study. Journal of Crohn's and colitis. pp. S536-S537. [Online].